Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • RESEARCH HIGHLIGHT

Peptide vaccine turns up the heat in ALK-positive cancers

  1. Alex Eccleston
    View author publications

    You can also search for this author in PubMed  Google Scholar

Non-small-cell lung cancer (NSCLC) with rearrangements in anaplastic lymphoma kinase (ALK) is treated with ALK-targeting tyrosine kinase inhibitors. However, resistance and disease progression occur and immune checkpoint inhibitors (ICIs) are not effective. In a recent study, Mota et al. have identified mouse and human immunogenic ALK peptides that induce cytotoxic T cell responses. When combined with an ALK inhibitor and ICI, an ALK peptide vaccine eradicates lung tumours and prevents metastasis in mouse models.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 22, 696 (2023)

doi: https://doi.org/10.1038/d41573-023-00123-8

References

  1. Mota, I. et al. ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer. Nat. Cancer 4, 1016–1035 (2023)

    Article  PubMed  Google Scholar 

Download references

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links